Testing OPB-201 cell therapy for recurrent endometrial cancer and platinum-resistant ovarian cancer
Tests OPB-201, made from a person's own T cells, in recurrent endometrial or ovarian cancer.
Plain-language title generated from the registry record
Registry title: A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Key facts
- Where
- Atlanta, Detroit, Houston, Minneapolis, and San Francisco, United StatesSee the 5 sites
- Phase
- Phase 1
Where in United States
- Emory Winship Cancer InstituteAtlanta, United StatesTaking people
- Karmanos Cancer InstituteDetroit, United StatesTaking people
- MD Anderson Cancer CenterHouston, United StatesTaking people
- University of MinnesotaMinneapolis, United StatesTaking people
- UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Outpace Bio, Inc.
- Trial code
- NCT07664735
- Record updated
- 26 October 2026
- Original description
The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.Read full original descriptionShow less
A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.
Inclusion: Age ≥ 18 years of age at the time of signing the informed consent form; Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings; Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy; Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation; Measurable disease; Consent to provide archived tumor tissue sample; ECOG performance status of 0 or 1; Adequate organ function; HLA-A *02:01 or HLA-A *02:02; PRAME positive tumor.
Exclusion: Had an allogenic tissue/solid organ transplant; Concurrent treatment with systemic high dose corticosteroids; Unresolved acute effects of any prior therapy; Uncontrolled bacterial, fungal, or viral infections; Active infection requiring systemic therapy; Bleeding or thrombotic disorders or at risk for severe hemorrhage; Active autoimmune disease; Women of child-bearing potential who are pregnant or breastfeeding; Any form of primary immunodeficiency; Other exclusions as stated in the protocol.